To improve the lives of patients affected by transthyretin amyloidoses through innovative therapeutic approaches.
Polyneuropathy and CNS Angiopathy
What is happening in our universe.
BSIM Therapeutics announces selection of candidate compound for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BSIM Therapeutics is awarded a second US Patent
BSIM at the "3rd European ATTR Amyloidosis meeting for Patients and Doctors"
Trademark "BSIM Therapeutics" registered in the US
By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more